Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 167Leukemia 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 71Lymphoma 51Myelodysplastic Syndromes 38Congenital Abnormalities 32Burkitt Lymphoma 29Lymphoma, Non-Hodgkin 27Recurrence 26Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Lymphoma, Mantle-Cell 23Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 21Hodgkin Disease 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 13Myeloproliferative Disorders 12Leukemia, Myelomonocytic, Chronic 11Leukemia, Biphenotypic, Acute 11Leukemia, Eosinophilic, Acute 9Blast Crisis 9Lymphoma, B-Cell 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Anemia, Refractory, with Excess of Blasts 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 7Multiple Myeloma 7Leukemia, Basophilic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

venetoclax 1magrolimab 1cc-486 1Mitoxantrone 1Etoposide 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloid Malignancies × Cytarabine × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡